197 related articles for article (PubMed ID: 25518732)
21. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.
Zabaleta A; Arribillaga L; Llopiz D; Dotor J; Lasarte JJ; Prieto J; Borrás-Cuesta F; Esteban JI; Quer J; Vayreda F; Sarobe P
Antiviral Res; 2007 Apr; 74(1):25-35. PubMed ID: 17275104
[TBL] [Abstract][Full Text] [Related]
22. Regression of established AB1 murine mesothelioma induced by peritumoral injections of CpG oligodeoxynucleotide either alone or in combination with poly(I:C) and CD40 ligand plasmid DNA.
Stone GW; Barzee S; Snarsky V; Santucci C; Tran B; Kornbluth RS
J Thorac Oncol; 2009 Jul; 4(7):802-8. PubMed ID: 19550243
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma.
Murillo O; Arina A; Hervas-Stubbs S; Gupta A; McCluskey B; Dubrot J; Palazón A; Azpilikueta A; Ochoa MC; Alfaro C; Solano S; Pérez-Gracia JL; Oyajobi BO; Melero I
Clin Cancer Res; 2008 Nov; 14(21):6895-906. PubMed ID: 18980984
[TBL] [Abstract][Full Text] [Related]
24. Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist.
Hosoya T; Sato-Kaneko F; Ahmadi A; Yao S; Lao F; Kitaura K; Matsutani T; Carson DA; Hayashi T
Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6836-E6844. PubMed ID: 29967183
[TBL] [Abstract][Full Text] [Related]
25. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
26. Deliberately provoking local inflammation drives tumors to become their own protective vaccine site.
Jackaman C; Lew AM; Zhan Y; Allan JE; Koloska B; Graham PT; Robinson BW; Nelson DJ
Int Immunol; 2008 Nov; 20(11):1467-79. PubMed ID: 18824504
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant anti-tumor vaccination prior to surgery enhances survival.
Fisher SA; Cleaver A; Lakhiani DD; Khong A; Connor T; Wylie B; Lesterhuis WJ; Robinson BW; Lake RA
J Transl Med; 2014 Sep; 12():245. PubMed ID: 25186961
[TBL] [Abstract][Full Text] [Related]
28. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
Nowak AK; Robinson BW; Lake RA
Cancer Res; 2003 Aug; 63(15):4490-6. PubMed ID: 12907622
[TBL] [Abstract][Full Text] [Related]
29. Generation of a soluble recombinant trimeric form of bovine CD40L and its potential use as a vaccine adjuvant in cows.
Pujol J; Bouillenne F; Farnir F; Dufrasne I; Mainil J; Galleni M; Lekeux P; Bureau F; Fiévez L
Vet Immunol Immunopathol; 2015 Nov; 168(1-2):1-13. PubMed ID: 26553560
[TBL] [Abstract][Full Text] [Related]
30. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions.
Redondo P; del Olmo J; López-Diaz de Cerio A; Inoges S; Marquina M; Melero I; Bendandi M
J Invest Dermatol; 2007 Jul; 127(7):1673-80. PubMed ID: 17380112
[TBL] [Abstract][Full Text] [Related]
31. Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1.
Liu HC; Viswanath DI; Pesaresi F; Xu Y; Zhang L; Di Trani N; Paez-Mayorga J; Hernandez N; Wang Y; Erm DR; Ho J; Susnjar A; Liu X; Demaria S; Chen SH; Teh BS; Butler EB; Xuan Chua CY; Grattoni A
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):492-506. PubMed ID: 32768562
[TBL] [Abstract][Full Text] [Related]
32. A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models.
Adlard AL; Dovedi SJ; Telfer BA; Koga-Yamakawa E; Pollard C; Honeychurch J; Illidge TM; Murata M; Robinson DT; Jewsbury PJ; Wilkinson RW; Stratford IJ
Int J Cancer; 2014 Aug; 135(4):820-9. PubMed ID: 24390981
[TBL] [Abstract][Full Text] [Related]
33. Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects.
Welniak LA; Shorts L; Subleski J; Blazar BR; Wiltrout RH; Murphy WJ
Biol Blood Marrow Transplant; 2004 Aug; 10(8):534-9. PubMed ID: 15282531
[TBL] [Abstract][Full Text] [Related]
34. Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8
Rolig AS; Rose DC; McGee GH; Rubas W; Kivimäe S; Redmond WL
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35444059
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors.
Aranda F; Llopiz D; Díaz-Valdés N; Riezu-Boj JI; Bezunartea J; Ruiz M; Martínez M; Durantez M; Mansilla C; Prieto J; Lasarte JJ; Borrás-Cuesta F; Sarobe P
Cancer Res; 2011 May; 71(9):3214-24. PubMed ID: 21402711
[TBL] [Abstract][Full Text] [Related]
36. Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy.
Broomfield S; Currie A; van der Most RG; Brown M; van Bruggen I; Robinson BW; Lake RA
Cancer Res; 2005 Sep; 65(17):7580-4. PubMed ID: 16140921
[TBL] [Abstract][Full Text] [Related]
37. Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity.
Balkow S; Loser K; Krummen M; Higuchi T; Rothoeft T; Apelt J; Tuettenberg A; Weishaupt C; Beissert S; Grabbe S
Exp Dermatol; 2009 Jan; 18(1):78-87. PubMed ID: 19054060
[TBL] [Abstract][Full Text] [Related]
38. Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma.
Sciullo PD; Menay F; Cocozza F; Gravisaco MJ; Waldner CI; Mongini C
Clin Immunol; 2019 Jun; 203():154-161. PubMed ID: 31048012
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer.
Fransen MF; Cordfunke RA; Sluijter M; van Steenbergen MJ; Drijfhout JW; Ossendorp F; Hennink WE; Melief CJ
Vaccine; 2014 Mar; 32(15):1654-60. PubMed ID: 24508038
[TBL] [Abstract][Full Text] [Related]
40. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy.
Chen Q; Xu L; Liang C; Wang C; Peng R; Liu Z
Nat Commun; 2016 Oct; 7():13193. PubMed ID: 27767031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
